GlassScriptPhysician profile
Robert M Harris
NPI 1841278553
$775.68
in general payments reported to CMS, 2019-2025
22 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $102 · 2023: $188 · 2024: $139 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81.02 | 2021-2025 | Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $58.84 | 2023 | Bexsero, Shingrix, Pediarix |
| Merck Sharp & Dohme LLC | $54.75 | 2021-2022 | |
| Novo Nordisk INC | $47.39 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.71 | 2021-2022 | |
| Cranial Technologies, INC | $38.19 | 2023-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $37.92 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $37.75 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.71 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $35.19 | 2022-2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $33.80 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.58 | 2022 | |
| Phadia US INC. | $32.67 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.27 | 2023 | Quviviq |
| Dexcom, INC. | $31.67 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $31.57 | 2024 | Aptima |
| Abbott Laboratories | $31.17 | 2021 | |
| Sobi, INC | $21.78 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.39 | 2025 | Qelbree |
| Sanofi Pasteur INC. | $13.18 | 2022 | |
| Seqirus USA INC | $12.97 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.